MedTrace Logo

Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids

NCT00709579 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-07-08

No results posted yet for this study

Summary

Methodology :Phase III study, single centre, double blind, versus excipient, randomised, controlateral design.

Selection of the patients :Number of subjects required 60 :

* 30 patients needing an oral corticotherapy
* 30 patients needing a topical corticotherapy

Conditions

  • Cortico Atrophy

Interventions

DRUG

RV3391A

A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.

DRUG

Placebo

placebo

Sponsors & Collaborators

  • University Paul Sabatier of Toulouse

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • Centre Européen de Recherche sur la Peau,

    collaborator UNKNOWN

  • Pierre Fabre BIOMETRIE

    collaborator UNKNOWN

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Principal Investigators

  • Laurent Sailler, Professor · Centre Hospitalier Universitaire

  • Anne-Marie Schmitt, Doctor · Pierre Fabre Dermo Cosmetique

  • Carle Paul, Professor · Centre Hospitalier Universitaire

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709579 on ClinicalTrials.gov